Clinical research on rare diseases of children: neuroblastoma

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: Early access to new treatment options should not preclude accurate research planning, especially for rare diseases and fragile populations. Taking neuroblastoma as a model case, we analyzed the rationale supporting the search for future therapeutic strategies in the light of preclinical and clinical evidence. Methods: We reviewed ongoing randomized trials of pharmacological interventions for the treatment of neuroblastoma retrieved by searching ClinicalTrials.gov and the European Union Clinical Trials Registry (last update March 2016). Results: Our search identified four randomized clinical trial reports. We found poor evidence from preclinical and early clinical research supporting their rationale. Their methodology was questionable too. Conclusions: The urgency to cover unmet needs in difficult clinical settings like rare diseases, particularly those involving fragile populations, cannot justify disorderly research approaches. Under these circumstances, clinical questions should be properly identified and addressed to protect patients and avoid wasteful research.

Original languageEnglish
Pages (from-to)267-273
Number of pages7
JournalCancer Chemotherapy and Pharmacology
Volume79
DOIs
Publication statusPublished - 2017

Fingerprint

Rare Diseases
Neuroblastoma
Research
European Union
Population
Registries
Therapeutics
Randomized Controlled Trials
Clinical Trials
Pharmacology
Planning

Keywords

  • Clinical trials
  • Fragile populations
  • Neuroblastoma
  • Pediatric cancer
  • Rare diseases

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

@article{bb1803dacc054095af4c60f0ddb59724,
title = "Clinical research on rare diseases of children: neuroblastoma",
abstract = "Purpose: Early access to new treatment options should not preclude accurate research planning, especially for rare diseases and fragile populations. Taking neuroblastoma as a model case, we analyzed the rationale supporting the search for future therapeutic strategies in the light of preclinical and clinical evidence. Methods: We reviewed ongoing randomized trials of pharmacological interventions for the treatment of neuroblastoma retrieved by searching ClinicalTrials.gov and the European Union Clinical Trials Registry (last update March 2016). Results: Our search identified four randomized clinical trial reports. We found poor evidence from preclinical and early clinical research supporting their rationale. Their methodology was questionable too. Conclusions: The urgency to cover unmet needs in difficult clinical settings like rare diseases, particularly those involving fragile populations, cannot justify disorderly research approaches. Under these circumstances, clinical questions should be properly identified and addressed to protect patients and avoid wasteful research.",
keywords = "Clinical trials, Fragile populations, Neuroblastoma, Pediatric cancer, Rare diseases",
author = "Chiara Gerardi and Rita Banzi and Vittorio Bertele’ and Silvio Garattini",
year = "2017",
doi = "10.1007/s00280-016-3195-3",
language = "English",
volume = "79",
pages = "267--273",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Clinical research on rare diseases of children

T2 - neuroblastoma

AU - Gerardi, Chiara

AU - Banzi, Rita

AU - Bertele’, Vittorio

AU - Garattini, Silvio

PY - 2017

Y1 - 2017

N2 - Purpose: Early access to new treatment options should not preclude accurate research planning, especially for rare diseases and fragile populations. Taking neuroblastoma as a model case, we analyzed the rationale supporting the search for future therapeutic strategies in the light of preclinical and clinical evidence. Methods: We reviewed ongoing randomized trials of pharmacological interventions for the treatment of neuroblastoma retrieved by searching ClinicalTrials.gov and the European Union Clinical Trials Registry (last update March 2016). Results: Our search identified four randomized clinical trial reports. We found poor evidence from preclinical and early clinical research supporting their rationale. Their methodology was questionable too. Conclusions: The urgency to cover unmet needs in difficult clinical settings like rare diseases, particularly those involving fragile populations, cannot justify disorderly research approaches. Under these circumstances, clinical questions should be properly identified and addressed to protect patients and avoid wasteful research.

AB - Purpose: Early access to new treatment options should not preclude accurate research planning, especially for rare diseases and fragile populations. Taking neuroblastoma as a model case, we analyzed the rationale supporting the search for future therapeutic strategies in the light of preclinical and clinical evidence. Methods: We reviewed ongoing randomized trials of pharmacological interventions for the treatment of neuroblastoma retrieved by searching ClinicalTrials.gov and the European Union Clinical Trials Registry (last update March 2016). Results: Our search identified four randomized clinical trial reports. We found poor evidence from preclinical and early clinical research supporting their rationale. Their methodology was questionable too. Conclusions: The urgency to cover unmet needs in difficult clinical settings like rare diseases, particularly those involving fragile populations, cannot justify disorderly research approaches. Under these circumstances, clinical questions should be properly identified and addressed to protect patients and avoid wasteful research.

KW - Clinical trials

KW - Fragile populations

KW - Neuroblastoma

KW - Pediatric cancer

KW - Rare diseases

UR - http://www.scopus.com/inward/record.url?scp=84996536260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996536260&partnerID=8YFLogxK

U2 - 10.1007/s00280-016-3195-3

DO - 10.1007/s00280-016-3195-3

M3 - Article

AN - SCOPUS:84996536260

VL - 79

SP - 267

EP - 273

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

ER -